— Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability — Study initiation on track, with first participants expected to be dosed in the second half of 2026 Antwerp, Belgium, June 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB)